CN116570665A - 一种眼部熏蒸组合物、熏蒸液及其制备方法和应用 - Google Patents
一种眼部熏蒸组合物、熏蒸液及其制备方法和应用 Download PDFInfo
- Publication number
- CN116570665A CN116570665A CN202310467291.4A CN202310467291A CN116570665A CN 116570665 A CN116570665 A CN 116570665A CN 202310467291 A CN202310467291 A CN 202310467291A CN 116570665 A CN116570665 A CN 116570665A
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- fumigation
- eye
- pipewort
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000003958 fumigation Methods 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims description 10
- 239000007788 liquid Substances 0.000 title description 4
- 239000000284 extract Substances 0.000 claims abstract description 126
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 25
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 25
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 25
- 240000000249 Morus alba Species 0.000 claims abstract description 25
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 25
- 244000112814 pipewort Species 0.000 claims abstract description 24
- 241001113925 Buddleja Species 0.000 claims abstract description 20
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 20
- 229940067866 dandelion extract Drugs 0.000 claims abstract description 20
- 235000020691 dandelion extract Nutrition 0.000 claims abstract description 20
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 20
- 239000001845 taraxacum officinale leaf extract Substances 0.000 claims abstract description 20
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 235000011477 liquorice Nutrition 0.000 claims abstract description 18
- 238000010438 heat treatment Methods 0.000 claims abstract description 12
- 239000000243 solution Substances 0.000 claims description 29
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 22
- 241000123846 Buddleja officinalis Species 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 11
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 239000011550 stock solution Substances 0.000 claims description 6
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 4
- 206010013774 Dry eye Diseases 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000002458 infectious effect Effects 0.000 claims description 4
- 229940069445 licorice extract Drugs 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 2
- 208000022873 Ocular disease Diseases 0.000 claims description 2
- 229940010454 licorice Drugs 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 241000723353 Chrysanthemum Species 0.000 claims 7
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract description 19
- 208000024891 symptom Diseases 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 6
- 210000004175 meibomian gland Anatomy 0.000 abstract description 6
- 238000011084 recovery Methods 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 230000036770 blood supply Effects 0.000 abstract description 3
- 238000002636 symptomatic treatment Methods 0.000 abstract description 3
- 230000007547 defect Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 13
- 230000004438 eyesight Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 241000245665 Taraxacum Species 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 241000475481 Nebula Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 208000003464 asthenopia Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 208000005494 xerophthalmia Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- 241000202807 Glycyrrhiza Species 0.000 description 3
- 241000589902 Leptospira Species 0.000 description 3
- 230000004377 improving vision Effects 0.000 description 3
- 241000208838 Asteraceae Species 0.000 description 2
- 241000220485 Fabaceae Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- IECBDTGWSQNQID-JGVFFNPUSA-N (1r,5s)-4,6,6-trimethylbicyclo[3.1.1]hept-3-en-7-one Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2=O IECBDTGWSQNQID-JGVFFNPUSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 244000277285 Cassia obtusifolia Species 0.000 description 1
- 235000006719 Cassia obtusifolia Nutrition 0.000 description 1
- 244000201986 Cassia tora Species 0.000 description 1
- 235000014552 Cassia tora Nutrition 0.000 description 1
- IECBDTGWSQNQID-UHFFFAOYSA-N Chrysanthenon Natural products CC1=CCC2C(C)(C)C1C2=O IECBDTGWSQNQID-UHFFFAOYSA-N 0.000 description 1
- IECBDTGWSQNQID-SFYZADRCSA-N Chrysanthenone Natural products CC1=CC[C@H]2C(C)(C)[C@@H]1C2=O IECBDTGWSQNQID-SFYZADRCSA-N 0.000 description 1
- 206010009185 Ciliary muscle spasm Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 1
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 1
- 241000300213 Eriocaulon buergerianum Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 241000218213 Morus <angiosperm> Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000292546 Taraxacum mongolicum Species 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000006754 Taraxacum officinale Nutrition 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- -1 glycyrrhiza polysaccharide Chemical class 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本申请公开了一种眼部熏蒸组合物,包括如下重量份的组分:密蒙花提取液8‑12份、谷精草提取液7‑12份、菊花提取液8‑12份、蒲公英提取液4‑8份、桑叶提取液4‑8份、决明子提取液4‑8份、甘草提取液8‑12份。本申请眼部熏蒸组合物经过上述配伍成功克服了现有技术中治疗产品单纯对症治疗暂时缓解症状的弊端,应用眼部熏蒸联合眼表加热按摩既能促进睑板腺功能以及眼表血供的恢复,也促进了眼表炎症以及泪膜稳态的修复,起到了治标又治本的作用。
Description
技术领域
本申请涉及一种眼部熏蒸液及其制备方法和应用,属于眼部护理产品技术领域。
背景技术
随着人们生活方式的改变,干眼症的发病率在逐年增加,据统计,我国的干眼发病率占21%~30%。其主要病因为泪液分泌减少或蒸发迅速,从而导致的泪液的质、量和流动性发生异常,破坏泪膜稳定性,最终造成眼部不适感(灼烧感、异物感、干涩感等)的产生,严重的干眼症患者视觉功能甚至会受到影响。目前,市面上存在大量干眼治疗产品,包括湿润眼表的人工泪液、促进眼表局部血液循环的加热眼贴、按摩仪等,这些产品均以对症治疗为主,即只能暂时缓解症状,缺少远期治疗效益。因此,创新的治疗手段需兼顾治疗的时效性,并能长久维持。
发明内容
根据本申请的一个方面,提供了一种眼部熏蒸组合物,由密蒙花、谷精草,菊花、蒲公英、桑叶、决明子、甘草的提取液配伍制备得到,其中配伍原则以密蒙花、谷精草养肝明目,清热退翳共为君药;菊花、蒲公英清肝明目,清热解毒,为臣药助君药明目退翳;佐以桑叶、决明子可滋阴润燥,平肝明目;以甘草清热缓解、调和诸药。本申请眼部熏蒸组合物经过上述配伍成功克服了现有技术中治疗产品单纯对症治疗暂时缓解症状的弊端,应用眼部熏蒸联合眼表加热按摩既能促进睑板腺功能以及眼表血供的恢复,也促进了眼表炎症以及泪膜稳态的修复,起到了治标又治本的作用。
本申请采用如下技术方案:
一种眼部熏蒸组合物,包括如下重量份的组分:
密蒙花提取液8-12份、谷精草提取液7-12份、菊花提取液8-12份、蒲公英提取液4-8份、桑叶提取液4-8份、决明子提取液4-8份、甘草提取液8-12份。
可选地,眼部熏蒸组合物包括如下重量份的组分:密蒙花提取液9-11份、谷精草提取液9-11份、菊花提取液9-11份、蒲公英提取液5-7份、桑叶提取液5-7份、决明子提取液5-7份、甘草提取液9-11份。
可选地,眼部熏蒸组合物包括如下重量份的组分:密蒙花提取液10份、谷精草提取液10份、菊花提取液10份、蒲公英提取液6份、桑叶提取液6份、决明子提取液6份、甘草提取液10份。
根据本申请的另一方面,提供了一种眼部熏蒸液,包括如下重量份的组分:密蒙花提取液8-12份、谷精草提取液7-12份、菊花提取液8-12份、蒲公英提取液4-8份、桑叶提取液4-8份、决明子提取液4-8份、甘草提取液8-12份、对羟基苯乙酮0.1-0.4份、辛酰羟肟酸0.1-0.4份、丁二醇0.1-0.4份、水56-62份。
可选地,眼部熏蒸液包括如下重量份的组分:密蒙花提取液9-11份、谷精草提取液9-11份、菊花提取液9-11份、蒲公英提取液5-7份、桑叶提取液5-7份、决明子提取液5-7份、甘草提取液9-11份、对羟基苯乙酮0.1-0.2份、辛酰羟肟酸0.1-0.2份、丁二醇0.1-0.2份、水57-61份。
可选地,眼部熏蒸液包括如下重量份的组分:密蒙花提取液10份、谷精草提取液10份、菊花提取液10份、蒲公英提取液6份、桑叶提取液6份、决明子提取液6份、甘草提取液10份、对羟基苯乙酮0.2份、辛酰羟肟酸0.2份、丁二醇0.2份、水58份。
密蒙花为醉鱼草科醉鱼草属植物密蒙花Buddleja officinalis Maxim.的干燥花蕾。具有清热泻火,养肝明目,退翳的功效。本品提取液所含刺槐素有维生素P样作用,能减轻眼部应激性炎症,能降低黏膜、血管的通透性及脆性,有缓解视疲劳的作用。
谷精草为谷精草科谷精草属植物谷精草Eriocaulon buergerianum Koern的干燥带花蕾的头状花序。具有明目退翳,疏散风热的功效。本品提取液所含谷精草素对眼部葡萄球菌、绿脓杆菌、肺炎双球菌、大肠杆菌、真菌均有明显抑制作用。
菊花为菊科菊属植物菊Chrysanthemum morifolium Ramat的干燥头状花序。具有清肝明目,清热解毒,疏散风热,平抑肝阳的功效。本品提取液所含菊油环酮、菊苷对眼部金黄色葡萄球菌、多种致病性杆菌及真菌均有抑制作用,对病毒PR3和钩端螺旋体也有抑制作用。
蒲公英为菊科蒲公英属植物蒲公英Taraxacum mongolicum Hand植物的干燥全草。具有清肝明目,清热解毒,消肿散结的功效。本品提取液所含公英固醇、蒲公英素、蒲公英苦素、蒲公英赛醇对眼部金黄色葡萄球菌、溶血性链球菌及卡他球菌有较强的抑制作用,对肺炎双球菌、脑膜炎双球菌、白喉杆菌、福氏痢疾杆菌、绿脓杆菌及钩端螺旋体等也有一定的抑制作用。
桑叶为桑科桑属植物桑Morus alba L的干燥叶。具有清肝明目,平抑肝阳,疏散风热的功效。本品提取液所含脱皮固酮、桑苷、槲皮素、东莨菪素对金黄色葡萄球菌、乙型溶血性链球菌等眼部多种致病菌有抑制作用,对钩端螺旋体有明显抑制作用,可缓解眼部睫状肌痉挛引起的视疲劳。
决明子为豆科决明属植物决明Cassia obtusifolia L的干燥成熟种子。具有清热明目,泻火润燥的功效。本品提取液所含决明子素、大黄素有明显的抗眼部病原微生物作用,对细胞免疫功能有抑制作用,对巨噬细胞吞噬功能有增强作用。
甘草为豆科甘草属植物植物甘草Glycyrrhiza uralensis Fisc的干燥根和根茎。具有热解毒,缓急止痛,调和药性的功效。本品提取液所含甘草皂苷、甘草醇对金黄色葡萄球菌、结核杆菌、大肠杆菌、阿米巴原虫及滴虫均有抑制作用;甘草多糖对腺病毒Ⅲ型、单纯疱疹病毒Ⅰ型、水泡性口炎病毒和牛痘病毒均有明显抑制作用。
可选地,密蒙花、谷精草,菊花、蒲公英、桑叶、决明子、甘草的提取液制备采用如下方法:选取上述植物的干品,洗净,沥干,破碎成2~3cm颗粒段,烘干,按干重加6倍水,于80-85℃加热6h,过滤,取滤液,在40-43℃下真空浓缩至约相当于密蒙花10~30g/ml,其中真空度为0.095Mpa。
根据本申请的另一方面提供了一种上述眼部熏蒸液的制备方法,包括如下步骤:
S1、将密蒙花提取液置于反应器中,加热;
S2、向步骤S1中密蒙花提取液中依次保温加入谷精草提取液、菊花提取液、蒲公英提取液、桑叶提取液、决明子提取液、甘草提取液,混合均匀,得到眼部熏蒸组合物原液;
S3、向步骤S2的眼部熏蒸组合物原液中加入对羟基苯乙酮、辛酰羟肟酸、丁二醇、水,混合均匀得到所述眼部熏蒸液。
可选地,所述密蒙花提取液与谷精草提取液、菊花提取液、蒲公英提取液、桑叶提取液、决明子提取液、甘草提取液的重量比为1:(9-11):(9-11):(5-7):(5-7):(5-7):(9-11)。
可选地,所述密蒙花提取液与对羟基苯乙酮、辛酰羟肟酸、丁二醇、水的重量比为1:(0.1-0.4):(0.1-0.4):(0.1-0.4):(56-62)。
可选地,所述密蒙花提取液与谷精草提取液、菊花提取液、蒲公英提取液、桑叶提取液、决明子提取液、甘草的浓度独立地为10~30mg/mL。
提取液为液体或膏状。
可选地,所述步骤S1中,所述加热的条件为搅拌并加热至80-85℃。
可选地,所述步骤S2中,还包括混合均匀后保温至提取液完全溶解。
可选地,所述步骤S3中,还包括先将眼部熏蒸组合物降温至40-43℃。
根据本申请的另一方面,还提供了一种上述眼部熏蒸组合物、上述眼部熏蒸液、上述制备方法制备得到的眼部熏蒸液中的至少一种在制备用于感染性眼部疾病治疗产品中的应用。
可选地,所述应用包括用于制备干眼治疗产品。
用于感染性眼部疾病治疗产品在治疗期间忌辛辣。
本申请能产生的有益效果包括:
本申请提供的眼部熏蒸组合物,应用与对部分感染性眼部疾病治疗的眼部熏蒸液联合眼表加热按摩既能促进睑板腺功能以及眼表血供的恢复,也促进了眼表炎症以及泪膜稳态的修复,起到了治标又治本的作用,成本低、无副作用,可对眼部进行有效保护,能够明显缓解和治疗眼部干涩、痒、痛、胀,缓解视疲劳和视力下降。
具体实施方式
下面结合实施例详述本申请,但本申请并不局限于这些实施例。
如无特别说明,本申请的实施例中的原料均通过商业途径购买。
本申请中密蒙花、谷精草,菊花、蒲公英、桑叶、决明子、甘草的提取液通过商业途径购买符合浓度要求的商品成品或采用如下方法制备:选取上述植物的干品,洗净,沥干,破碎成2~3cm颗粒段,烘干,按干重加6倍水,于80-85℃加热6h,过滤,取滤液,在40-43℃下真空浓缩至约相当于密蒙花10~30g/ml,其中真空度为0.095Mpa。
实施例1眼部熏蒸液
眼部熏蒸液包括如下重量份的组分:密蒙花提取液10份、谷精草提取液10份、菊花提取液10份、蒲公英提取液6份、桑叶提取液6份、决明子提取液6份、甘草提取液10份、对羟基苯乙酮0.2份、辛酰羟肟酸0.2份、丁二醇0.2份、水58份。
上述眼部熏蒸液采用如下方法制备:
S1、将1kg密蒙花提取液置于反应器中,加热至82.5℃;
S2、向步骤S1中密蒙花提取液中依次保温加入1kg谷精草提取液、1kg菊花提取液、0.6kg蒲公英提取液、0.6kg桑叶提取液、0.6kg决明子提取液、1kg甘草提取液,混合均匀后保温至提取液完全溶解,然后降温至降温至41.5℃,得到眼部熏蒸组合物原液;
S3、向步骤S2的眼部熏蒸组合物原液中加入0.02kg对羟基苯乙酮、0.02kg辛酰羟肟酸、0.02kg丁二醇、5.8kg水,混合均匀得到所述眼部熏蒸液。
上述密蒙花提取液与谷精草提取液、菊花提取液、蒲公英提取液、桑叶提取液、决明子提取液、甘草的浓度独立地为20mg/mL。
测试例1
测试对象为大连医科大学附属第二医院眼科2021年11月至2022年4月就诊的100例干眼症患者。
测试对象治疗前具有以下症状:双眼异物感,灼烧感,干涩感,易视疲劳,角膜荧光染色及泪液分泌实验结果异常。
测试对象中的50名患者作为观察组,另外50名患者作为对照组。
观察组:玻璃酸钠滴眼液点眼,采用实施例1中的眼部熏蒸液熏蒸双眼配合睑板腺按摩。
对照组:玻璃酸钠滴眼液点眼,无菌注射用水熏蒸双眼配合睑板腺按摩。
测试结果如表1所示,根据表1结果可知,眼部熏蒸液联合睑板腺按摩可更有效的治疗干眼症造成的眼表损伤,治疗满意度如表2所示,表2结果可知,眼部熏蒸液治疗增加了患者的满意度两组患者治疗后不良反应比较,不良反应情况如表3所示,根据表3结果可知,眼部熏蒸液治疗可减少不良反应的发生,且所有不良反应均在治疗后得到好转。
表1两组患者治疗后眼表功能比较
表2两组患者治疗自觉感受比较
表3两组患者治疗后不良反应比较
以上所述,仅是本申请的几个实施例,并非对本申请做任何形式的限制,虽然本申请以较佳实施例揭示如上,然而并非用以限制本申请,任何熟悉本专业的技术人员,在不脱离本申请技术方案的范围内,利用上述揭示的技术内容做出些许的变动或修饰均等同于等效实施案例,均属于技术方案范围内。
Claims (10)
1.一种眼部熏蒸组合物,其特征在于,包括如下重量份的组分:
密蒙花提取液8-12份、谷精草提取液7-12份、菊花提取液8-12份、蒲公英提取液4-8份、桑叶提取液4-8份、决明子提取液4-8份、甘草提取液8-12份。
2.根据权利要求1所述的眼部熏蒸组合物,其特征在于,包括如下重量份的组分:密蒙花提取液9-11份、谷精草提取液9-11份、菊花提取液9-11份、蒲公英提取液5-7份、桑叶提取液5-7份、决明子提取液5-7份、甘草提取液9-11份。
3.一种眼部熏蒸液,其特征在于,包括如下重量份的组分:密蒙花提取液8-12份、谷精草提取液7-12份、菊花提取液8-12份、蒲公英提取液4-8份、桑叶提取液4-8份、决明子提取液4-8份、甘草提取液8-12份、对羟基苯乙酮0.1-0.4份、辛酰羟肟酸0.1-0.4份、丁二醇0.1-0.4份、水56-62份。
4.根据权利要求3所述的眼部熏蒸液,其特征在于,包括如下重量份的组分:密蒙花提取液9-11份、谷精草提取液9-11份、菊花提取液9-11份、蒲公英提取液5-7份、桑叶提取液5-7份、决明子提取液5-7份、甘草提取液9-11份、对羟基苯乙酮0.1-0.2份、辛酰羟肟酸0.1-0.2份、丁二醇0.1-0.2份、水57-61份。
5.权利要求3或4所述眼部熏蒸液的制备方法,其特征在于,包括如下步骤:
S1、将密蒙花提取液置于反应器中,加热;
S2、向步骤S1的密蒙花提取液中依次保温加入谷精草提取液、菊花提取液、蒲公英提取液、桑叶提取液、决明子提取液、甘草提取液,混合均匀,得到眼部熏蒸组合物原液;
S3、向步骤S2的眼部熏蒸组合物原液中加入对羟基苯乙酮、辛酰羟肟酸、丁二醇、水,混合均匀得到所述眼部熏蒸液。
6.根据权利要求5所述的制备方法,其特征在于,所述密蒙花提取液与谷精草提取液、菊花提取液、蒲公英提取液、桑叶提取液、决明子提取液、甘草提取液的重量比为1:(9-11):(9-11):(5-7):(5-7):(5-7):(9-11);
优选地,所述密蒙花提取液与对羟基苯乙酮、辛酰羟肟酸、丁二醇、水的重量比为1:(0.1-0.4):(0.1-0.4):(0.1-0.4):(56-62)。
7.根据权利要求5所述的制备方法,其特征在于,所述密蒙花提取液与谷精草提取液、菊花提取液、蒲公英提取液、桑叶提取液、决明子提取液、甘草的浓度独立地为10~30mg/mL。
8.根据权利要求5所述的制备方法,其特征在于,所述步骤S1中,所述加热的条件为搅拌并加热至80-85℃;
优选地,所述步骤S2中,还包括混合均匀后保温至提取液完全溶解;
优选地,所述步骤S3中,还包括先将眼部熏蒸组合物降温至40-43℃。
9.权利要求1或2所述的眼部熏蒸组合物、权利要求3或4所述的眼部熏蒸液、根据权利要求5至8任一项所述制备方法制备得到的眼部熏蒸液中的至少一种在制备用于感染性眼部疾病治疗产品中的应用。
10.根据权利要求9所述的应用,其特征在于,所述应用包括用于制备干眼治疗产品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310467291.4A CN116570665A (zh) | 2023-04-26 | 2023-04-26 | 一种眼部熏蒸组合物、熏蒸液及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310467291.4A CN116570665A (zh) | 2023-04-26 | 2023-04-26 | 一种眼部熏蒸组合物、熏蒸液及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116570665A true CN116570665A (zh) | 2023-08-11 |
Family
ID=87536911
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310467291.4A Pending CN116570665A (zh) | 2023-04-26 | 2023-04-26 | 一种眼部熏蒸组合物、熏蒸液及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116570665A (zh) |
-
2023
- 2023-04-26 CN CN202310467291.4A patent/CN116570665A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102198236B (zh) | 一种治疗急性鼻窦炎的中药组合物及其制备方法 | |
CN104873446B (zh) | 一种含肉桂油的牙膏 | |
CN113730479A (zh) | 一种具有保健功能的组合物及其制备方法与用途 | |
CN110639010A (zh) | 适用于眼部的含有重组水蛭素中药组合物及制备方法 | |
CN116115689A (zh) | 七窍通鼻炎喷剂及其制备方法 | |
CN116570665A (zh) | 一种眼部熏蒸组合物、熏蒸液及其制备方法和应用 | |
CN110882332B (zh) | 一种抑菌、抗炎、抗过敏的鼻用中药组合物及其制备方法和用途 | |
CN112353883A (zh) | 治疗近视飞蚊症的眼药水的制备方法 | |
CN111632080A (zh) | 一种治疗药疹皮炎的配方及制备方法及应用 | |
CN102940753B (zh) | 一种治疗青光眼的药丸及制备方法 | |
CN105194443A (zh) | 一种用于治疗小儿湿疹的中药组合物及其制备方法 | |
CN104623304A (zh) | 一种治疗湿热毒蕴型慢性皮肤溃疡的洗剂及其制备方法 | |
CN105943718B (zh) | 一种沉香复方中药组合物及其制备方法、应用 | |
CN115089633B (zh) | 一种防治近视的组合物、眼贴及制备方法 | |
CN110638891A (zh) | 一种止咳口服液 | |
CN114159536B (zh) | 药物组合物及其制备方法和应用 | |
CN104306734B (zh) | 治疗糖尿病坏疽外用膏药制剂及其制备方法 | |
CN113559195B (zh) | 一种外用痔疮药、痔疮蒸洗液及其制备方法 | |
CN114259517B (zh) | 一种治疗变应性鼻炎的中药香薰凝胶 | |
CN115414427B (zh) | 治疗慢性皮肤瘙痒症的中药组合物及其制备方法、用途 | |
CN115414415B (zh) | 一种治疗皮肤外伤及溃烂的中药组合物及制备方法 | |
CN104958400A (zh) | 一种治疗急性结膜炎的眼膏及其制备方法 | |
CN104906217A (zh) | 一种治疗急性卡他性结膜炎的中药膏剂及其制备方法 | |
CN104906379A (zh) | 一种治疗大疱性脓包疮的中药软膏及其制备方法 | |
CN113876836A (zh) | 一种小儿外用泡脚的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |